Clinical Pharmacologists Warn of DTC Genomics Backlash on PGx
        
            By GenomeWeb, 
                GenomeWeb News
             | 07. 22. 2009
        
                    
                                    
                    
                                                                                                                                    
                                                                            
                              
    
  
  
    
  
          
  
      
    
            The American College of Clinical Pharmacy has called for federal oversight of direct-to-consumer genetic testing companies, which it believes could inadvertently hold back advances in clinical pharmacogenetic and pharmacogenomic testing.
In a position statement published in the Journal of Clinical Pharmacology, ACCP argued that consumer response to genetic testing advertising could have "both immediate and long-term effects on public health and the future adoption of pharmacogenetic/genomic testing."
The paper explains that consumers could be let down or confused by the performance of DTC genetic tests, which could have a negative impact on other genetic testing firms that do not market directly to consumers.
The ACCP likened consumer ads for genetic tests to those for prescription drugs, which are regulated by the US Food and Drug Administration's Division of Drug Marketing, Advertising, and Communications. The group noted that a similar oversight system is not yet in place for the young genetic testing field.
"Given the rate of development of genetic testing and its widespread availability and accessibility by the public, the establishment of effective governmental oversight needs to be undertaken...
 
       
 
  
 
    
    
  
   
                        
                                                                                
                 
                                                    
                            
                                  
    
  
  
      Related Articles
    
  
          
  
  
  
  
  
  
      
            
                  
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Megan Molteni and Anil Oza,  STAT | 10.07.2025
                                                        
     
    
    
            For two years, a panel of scientific experts, clinicians, and patient advocates had been hammering out ways to increase community engagement in National Institutes of Health-funded science. When they presented their road map to the NIH Director Jay Bhattacharya last...
 
       
 
 
  
      
    
    
    
    
            Paula Amato & Shoukhrat Mitalipov
[OHSU News/Christine Torres Hicks]
On September 30th, a team of 21 scientists from Oregon Health & Science University (OHSU) published a significant paper in Nature Communications, with a scientifically accurate but, to many, somewhat abstruse headline:
Induction of experimental cell division to generate cells with reduced chromosome ploidy
The lead authors were Shoukhrat Mitalipov, recently described here as “a push-the-envelope biologist,” and his long-term colleague Paula Amato. (Recall that in July the pair had co-published with...
 
       
 
 
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Pam Belluck,  The New York Times | 10.17.2025
                                                        
     
    
    
            Before dawn on a March morning, Doug Whitney walked into a medical center 2,000 miles from home, about to transform from a mild-mannered, bespectacled retiree into a superhuman research subject.
First, a doctor inserted a needle into his back to...
 
       
 
 
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Julia Black,  MIT Technology Review | 10.16.2025
                                                        
     
    
    
            Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of...